This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul H. Lipkin, MD; Ilene J. Goldstein, MD; Andrew R. Adesman, MD

Arch Pediatr Adolesc Med. 1994;148(8):859-861.

Abstract
Objective
To determine the incidence of tics or dyskinesias (T/D) and examine associated clinical factors in children treated with stimulant medications for attention-deficit hyperactivity disorder.

Design
Cross-sectional analysis of a clinic cohort with chart review.

Setting
Hospital-based clinical service within a division of developmental and behavioral pediatrics.

Patients
One hundred twenty-two children with attention-deficit hyperactivity disorder treated with stimulant medication. All children currently or recently treated were included.

Interventions
None.

Measurements and Results
Determinations were made of medication used, medication dosage, presence or absence of T/D, time of T/D onset, and history and family history of T/D. Incidence of T/D was 9.0% of children or 8.2% of medication trials. One child (0.8%) had development of Tourette's syndrome. Age, medication, dosage, history of tics, or family history of tics was not related to onset of T/D.

Conclusion
Approximately 9% of children with attention-deficit hyperactivity disorder treated with stimulant medication had development of T/D, predominantly transient in nature, with less than 1% having development of chronic tics or Tourette's syndrome. Personal or family tic history, medication selection, or dosage was not related to onset of T/D.

(Arch Pediatr Adolesc Med. 1994;148:859-861)

Author Affiliations
From the Department of Pediatrics, Schneider Children's Hospital, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Biederman et al.
Pediatrics 2008;121:e73-e84.
ABSTRACT | FULL TEXT  

Methylphenidate-Induced Rabbit Syndrome
Mendhekar and Duggal
The Annals of Pharmacotherapy 2006;40:2076-2076.
FULL TEXT  

Atomoxetine Versus Stimulants for Treatment of Attention Deficit/Hyperactivity Disorder
Gibson et al.
The Annals of Pharmacotherapy 2006;40:1134-1142.
ABSTRACT | FULL TEXT  

A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder
Niederhofer et al.
J Psychopharmacol 2003;17:113-119.
ABSTRACT  

A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Scahill et al.
Am. J. Psychiatry 2001;158:1067-1074.
ABSTRACT | FULL TEXT  

The 4-Year Course of Tic Disorders in Boys With Attention-Deficit/Hyperactivity Disorder
Spencer et al.
Arch Gen Psychiatry 1999;56:842-847.
ABSTRACT | FULL TEXT  

Stimulant Medication Management of Students with Attention Deficit Hyperactivity Disorder: What Educators Need to Know
Scbulz and Edwards
Teacher Education and Special Education: The Journal of the Teacher Education Division of the Council for Exceptional Children 1997;20:170-178.
ABSTRACT  

TICS FROM HYPERACTIVITY DRUGS
JWatch General 1994;1994:8-8.
FULL TEXT